Whittier Trust Co. increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% in the third quarter, Holdings Channel reports. The institutional investor owned 48,260 shares of the medical research company’s stock after acquiring an additional 180 shares during the quarter. Whittier Trust Co.’s holdings in Thermo Fisher Scientific were worth $14,056,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Ellevest Inc. increased its stake in shares of Thermo Fisher Scientific by 137.5% in the second quarter. Ellevest Inc. now owns 95 shares of the medical research company’s stock worth $28,000 after buying an additional 55 shares during the last quarter. American National Bank bought a new stake in Thermo Fisher Scientific during the third quarter valued at $29,000. Massey Quick Simon & CO. LLC bought a new stake in Thermo Fisher Scientific during the second quarter valued at $30,000. Redhawk Wealth Advisors Inc. bought a new stake in Thermo Fisher Scientific during the second quarter valued at $31,000. Finally, Prestige Wealth Management Group LLC bought a new stake in Thermo Fisher Scientific during the second quarter valued at $32,000. Institutional investors and hedge funds own 88.22% of the company’s stock.

In related news, CEO Marc N. Casper sold 2,271 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $298.00, for a total value of $676,758.00. Following the sale, the chief executive officer now owns 283,502 shares of the company’s stock, valued at approximately $84,483,596. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jim P. Manzi sold 1,833 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $272.93, for a total value of $500,280.69. Following the completion of the sale, the director now directly owns 28,592 shares in the company, valued at approximately $7,803,614.56. The disclosure for this sale can be found here. Insiders have sold a total of 54,104 shares of company stock worth $15,418,539 in the last quarter. 0.45% of the stock is currently owned by company insiders.

Several analysts have weighed in on TMO shares. ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Barclays set a $330.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Monday, July 15th. Credit Suisse Group reiterated a “buy” rating and set a $310.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. Finally, Needham & Company LLC boosted their target price on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $305.27.

Shares of NYSE:TMO traded down $0.17 during trading on Friday, hitting $281.42. 1,171,587 shares of the company’s stock traded hands, compared to its average volume of 1,674,887. Thermo Fisher Scientific Inc. has a 52 week low of $208.34 and a 52 week high of $305.45. The company has a current ratio of 1.49, a quick ratio of 1.07 and a debt-to-equity ratio of 0.58. The company has a market cap of $112.77 billion, a price-to-earnings ratio of 25.31, a price-to-earnings-growth ratio of 1.84 and a beta of 1.13. The company has a 50-day moving average price of $288.69 and a 200-day moving average price of $281.30.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The business had revenue of $6.32 billion for the quarter, compared to analysts’ expectations of $6.31 billion. During the same quarter in the previous year, the business posted $2.75 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 3.9% on a year-over-year basis. On average, analysts predict that Thermo Fisher Scientific Inc. will post 12.25 earnings per share for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: What is the Bid-Ask Spread?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.